Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.46 |
| ▸ | PPARA | Q07869 | 13/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2862902 | 0.86 | PPARG (0.44) | PPARGPPARAACHEPPARD | |
| SCHEMBL4345882 | 0.83 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL4334205 | 0.82 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL1787452 | 0.81 | CYP3A4 (0.54) | CYP3A4LMNAACHEPARP1 | |
| SCHEMBL6655346 | 0.81 | PPARG (0.51) | PPARGPPARA | |
| SCHEMBL4348224 | 0.80 | GRIA2 (0.48) | PPARGPPARAPPARDSRR | |
| SCHEMBL2866290 | 0.80 | GRIA2 (0.48) | PPARGPPARAPPARDSRR | |
| SCHEMBL3156480 | 0.80 | SLC7A5 (0.59) | CYP3A4LMNA | |
| SCHEMBL694664 | 0.80 | TAAR1 (0.63) | CYP3A4LMNAACHEPARP1 | |
| SCHEMBL694663 | 0.80 | TAAR1 (0.63) | CYP3A4LMNAACHEPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816405-B2 | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090069591-A1 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1873141-A1 | CALCIUM BIS[2S)-3-[3-(2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2- FLUOROPROPOXY¨PHENYL]-2-ISOPROPOXYPROPIONATE] AND INTERMEDIATE THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | EISAI CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069591-A1 | Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof | CA2, CACNA1A, CACNA1C | PPARG 3388/4885PPARA 3168/4885CYP3A4 316/4885 |
| US-20070117866-A1 | Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof | CA2, CACNA1A, CACNA1C | PPARG 3388/4885PPARA 3168/4885CYP3A4 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.